Jianmin Pharmaceutical GroupLtd Yönetim

Yönetim kriter kontrolleri 3/4

Jianmin Pharmaceutical GroupLtd CEO'su Jun Wang, Sep2022 tarihinde atandı, in görev süresi 2.17 yıldır. şirketin hisselerinin 0.23% doğrudan sahiptir ve bu hisselerin değeri CN¥ 14.76M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 2.2 yıldır.

Anahtar bilgiler

Jun Wang

İcra Kurulu Başkanı

CN¥891.4k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.2yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	2.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jun Wang (47 yo)

2.2yrs

Görev süresi

CN¥891,400

Tazminat

Mr. Jun Wang was Vice President of KPC Pharmaceuticals,Inc until September 08, 2020. He is Managing Director of Jianmin Pharmaceutical Group Co.,Ltd. He is Director and President of Jianmin Pharmaceutical...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jun Wang	President	2.2yrs	CN¥891.40k	0.23% CN¥ 14.8m
Chaoyang Cheng	Financial Director	2.2yrs	CN¥511.20k	0.055% CN¥ 3.6m
Zhenbo Hu	VP & Director	1.3yrs	CN¥210.40k	Veri yok
Jie Zhou	Secretary	2.2yrs	CN¥408.80k	0.024% CN¥ 1.6m
Xuejun Pei	Vice President	2.2yrs	CN¥540.00k	0.12% CN¥ 7.8m
Zhijun Huang	Vice President	2.2yrs	CN¥540.00k	0.11% CN¥ 6.9m

2.2yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 600976 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jun Wang	President	2.2yrs	CN¥891.40k	0.23% CN¥ 14.8m
Zhenbo Hu	VP & Director	1.3yrs	CN¥210.40k	Veri yok
Qin He	Chairman	2.2yrs	CN¥2.10m	0.27% CN¥ 17.5m
Qijing Xiao	Chairman of the Supervisory Board	2.2yrs	Veri yok	Veri yok
Yunpei Guo	Independent Director	2.2yrs	CN¥90.00k	Veri yok
Rong Pei	Director	2.2yrs	CN¥60.00k	Veri yok
Liang Xu	Director	2.2yrs	CN¥60.00k	Veri yok
Shuqu Li	Independent Director	2.2yrs	CN¥90.00k	Veri yok
Hu Jian	Supervisor	2.2yrs	Veri yok	Veri yok
Li Chen	Supervisor	2.2yrs	Veri yok	Veri yok
Jingqiu Tang	Supervisor	2.2yrs	Veri yok	Veri yok
Zhi Yang	Independent Director	2.2yrs	CN¥90.00k	Veri yok

2.2yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600976 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Jianmin Pharmaceutical GroupLtd Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

No independent directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.54 (vs CN¥1.07 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 24%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.65 in 1Q 2023)

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings released: EPS: CN¥3.41 (vs CN¥2.68 in FY 2022)

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

Investor sentiment deteriorates as stock falls 16%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 16, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Full year 2022 earnings released: EPS: CN¥2.68 (vs CN¥2.13 in FY 2021)

Investor sentiment improves as stock rises 16%

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.59 in 3Q 2021)

Investor sentiment improved over the past week

Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.

Second quarter 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.64 in 2Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.45 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.25 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.60 in FY 2019)

Jianmin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥24.68

Third quarter earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day high - CN¥23.96

First half earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 13, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş